KUALA LUMPUR (Reuters) – Malaysia, which is negotiating supplies of a COVID-19 vaccine with China’s Sinovac Biotech, will only go ahead with procurement if it satisfies the safety and efficacy standards of local regulators, a minister said on Wednesday.
Malaysia will first review Sinovac’s clinical data before deciding, Science, Technology and Innovation Minister Khairy Jamaluddin said on Twitter, after Brazilian clinical trials found the efficacy of Sinovac’s vaccine to be well below the rate announced previously.
(Reporting by Joseph Sipalan; Editing by Ed Davies)
